News | March 13, 2024
Nirma acquires majority stake in Glenmark Life Sciences
Completes acquisition of 75% of share capital from Glenmark Pharmaceuticals
Completes acquisition of 75% of share capital from Glenmark Pharmaceuticals
Will continue to own a 7.84 per cent stake in Glenmark Life Sciences with the stake reduction
A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies
_256_384.jpg)
In Q2FY22, growth from Covid-driven products in the domestic branded formulation sales should dissipate on a QoQ basis as new covid cases have declined sharply. Vishal Manchanda, research analyst Nirmal Bang gives a preview of pharma companies in this report
403 entries from 22 states covering 168 districts highlight groundbreaking initiatives vital to improving national nutrition metrics.
The change is reflective of the company’s evolving vision aimed at further strengthening its global presence and a commitment to providing innovative solutions in the API and CDMO space
The Central government’s decision to exempt three more cancer medicines from customs duty is a commendable step towards making cancer drugs more affordable
Finance Minister Nirmala Sitharaman is set to present the full budget for the current financial year on July 23
The CDCCs are strategically positioned in regions identified as high-impact areas
Indian Pharma Post brings together the views of industry leaders on the Interim Union Budget 2024-25 announcement and its impact on the industry
Subscribe To Our Newsletter & Stay Updated
